The aim of this work was to develop a technological regulation for the production of probiotic based on lacto- and bifidobacteria in the form of intestinal-soluble capsules for farm animals. Three experimental series of probiotic drug were made in the form of enteric capsules based on lactic acid bacteria. It has been established that the Bifidobacterium adolectentis No 17-316 strain and the Lactobacillus plantarum No 7-317 strain are the most adapted for the bacterial consortium. These strains

more »

... have high biological activity and correspond to certain authentic characteristics. The pharmaceutical composition is proposed in the form of capsules with following ingredients: 50% of dry biomass of Lactobacillus plantarum No 7-317 and Bifidobacterium adolectentis No 17-316 strains, 5% of glucose, 5% of lactose, 9% of aerosil and 31% of starch. The content of lyophilized bacteria in one capsule is not less than 1 × 107 CFU of bifidobacteria/cm3 and 1 × 107 CFU of lactobacilli/cm3. A scheme of the manufacturing process of the drug in form of capsules includes the following stages: production of nutrient media and working solutions; growing cultures of lacto- and bifidobacteria, freeze drying of cultures of lacto- and bifidobacteria, obtaining a dry mass of lactic acid bacteria for encapsulation, encapsulation of the drug, control of the manufactured product before release, marking, packaging of capsules, transportation, storage of a drug.